FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Parathyroid Hormone (Natpara) Injection
Status: Currently in Shortage
»Date first posted: 09/11/2019
»Therapeutic Categories: Endocrinology/Metabolism

Expand all

Takeda Pharmaceuticals USA Inc. (Reverified 10/23/2019)

Company Contact Information:
866-888-0660

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25mcg Cartridge: (NDC 68875-0202-1); Carton: (NDC 68875-0202-2) (contains 2 cartridges) To be determined. Takeda is actively working to resolve the issue and resume supply. Updates will be provided on an ongoing basis. Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection

Dear Healthcare Provider Letter

Requirements related to complying with good manufacturing processes
50mcg Cartridge: (NDC 68875-0203-1); Carton: (NDC 68875-0203-2) (contains 2 cartridges) To be determined. Takeda is actively working to resolve the issue and resume supply. Updates will be provided on an ongoing basis. Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection

Dear Healthcare Provider Letter

Requirements related to complying with good manufacturing processes
75mcg Cartridge: (NDC 68875-0204-1); Carton: (NDC 68875-0204-2) (contains 2 cartridges) To be determined. Takeda is actively working to resolve the issue and resume supply. Updates will be provided on an ongoing basis. Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection

Dear Healthcare Provider Letter

Requirements related to complying with good manufacturing processes
100mcg Cartridge: (NDC 68875-0205-1); Carton: (NDC 68875-0205-2) (contains 2 cartridges) To be determined. Takeda is actively working to resolve the issue and resume supply. Updates will be provided on an ongoing basis. Important Information Regarding a Temporary Special Use Program for Obtaining and Using NATPARA® (Parathyroid Hormone) for Injection

Dear Healthcare Provider Letter

Requirements related to complying with good manufacturing processes

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English